Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00

АШУҮИС — Судалгааны мэдээлэл (CRIS)

Permanent URI for this communityhttps://library.mnums.edu.mn/handle/123456789/5001

Browse

Search Results

Now showing 1 - 10 of 11
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Нийслэлийн өргөө амаржих газарт хепатит В вирүсийн дархлаажуулалтанд хамрагдсан эмч, эмнэлгийн ажилтны дархлаа тогтоцыг үнэлэх нь
    (2021-06-10)
    Д.Оюун-Эрдэнэ
    ;
    Д.Адъяасүрэн
    ;
    ;
    М.Мэндбаяр
    ;
    Д.Уламбаяр
    Эмч, эмнэлгийн ажилтан ажил үүргээ гүйцэтгэх үед бохирлогдсон зүү тариурт хатгагдсанаас цусаар дамжих халдварт өртөх өндөр эрсдэлтэй байдаг. ДЭМБ-ын мэдээгээр анхаарал болгоомжгүйгээс энэ төрлийн гэмтэлд өртөж жил бүр эмнэлгийн 66.000 ажилтнууд хепатит В вирүсийн халдвар, 200-5000 ажилтан ХДХВ-ийн халдвараар халдварлагддаг байна. Цусаар дамжих халдвар дундаас хамгийн түгээмэл тохиолддог нь хепатит В, С вирүсийн болон ХДХВ-ийн халдвар байдаг. Зорилго: НӨАГ-ын хепатит В вирүсийн дархлаажуулалтанд хамрагдсан эмч, эмнэлгийн ажилтны дархлаа тогтоцыг үнэлэх. Арга зүй: Судалгааг проспектив аргаар, нэг агшингийн судалгааны загвар хэрэглэн гүйцэтгэсэн. НӨАГ-ын 331 эмч, эмнэлгийн ажилтан хепатит В вирусын дархлаажуулалт хамрагдсан байв. Үр дүн: Хепатит В вирүсийн эсрэг дархлаа тогтоцыг тодорхойлох шинжилгээнд хамрагдсан ажилтны насны хувьд 1824 нас 6 % (n=9), 25-44 нас 67 % (n=98), 45-64 нас 27% (n=40) байна. Дүгнэлт: Хепатит В вирүсийн эсрэг дархлаажуулалтын үр дүнд ажилтнуудын 66 хувьд дархлаа тогтсон байна. Хепатитын В вирүсийн халдвараас сэргийлэхийн тулд бүрэн тунгаар дархлаажуулалт хийлгэх нь илүү үр дүнтэй байгааг бидний судалгаа харуулж байна.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    P.367: Outcomes of liver transplantation: A single-center experience. (First Central Hospital of Mongolia).
    Methods: This study was conducted in Transplantation Center of the First Central Hospital of Mongolia between September 2011 and May 2023 on a total 200 patients have undergone liver transplantation. Results: There were 105 female patients out of 200, age between 18 months to 62 years old, and the average MELD score was 15±5.5, length of hospital stay were 31±13.94. These transplants were for liver (living donor=189, deceased donor=11, pediatric=7). The most causes of liver transplantation were liver cirrhosis due to HBV/HDV (59.5%), hepatocellular carcinoma (22.5%), primary biliary cirrhosis (5%), and only HBV related cirrhosis, alcoholic cirrhosis. There were 23(11.5%) biliary complication, 17 (8.5%) acute cellular rejection, hepatic artery thrombosis 2 (1%), and 3 cases retransplanted. The five year survival was 87%. Conclusions: This study provides the process of liver transplantation in First Central Hospital of Mongolia, and these positive outcomes support LT as an important therapy for end-stage liver disease and early hepatocellular carcinomas. Introduction: Liver transplantation (LT) is a main treatment of end-stage liver disease. Specially developing country like Mongolia has high prevalence of HBV, HDV, and hepatocellular cancer. Liver transplant is the second-most common solid organ transplant procedure in Mongolia. This study aimed to evaluate the efficacy of liver transplantation in the First Central Hospital of Mongolia.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Impact of Hepatitis D Coinfection on the Hepatitis Flare during Chemotherapy for B-Cell Non-Hodgkin Lymphoma
    (Mongolian National University of Medical Sciences, 2020-04-01) ;
    Anir Enkhbat
    ;
    Delgerbat Boldbaatar
    ;
    Khishigjargal Batsukh
    ;
    Altankhuu Murdoj
    Objectives: This study was conducted to determine the effect of Hepatitis B infection with or without D coinfection on the hepatitis flare associated with chemotherapy for B-Cell non-Hodgkin lymphoma. Methods: The hepatitis flare related to the chemotherapy for newly diagnosed B-Cell non-Hodgkin lymphoma was studied in HBV mono-infected and HBV and HDV coinfected patients between 2015 and 2018. Results: Nineteen HBsAg positive patients satisfied the inclusion criteria. In the group with the hepatitis flare, 14.3% were anti-HDV negative and 83.3% were anti-HDV positive (p<.006). Also, the hepatitis flare occurred in all patients where HDV-RNA was detected, while it had occurred in 60% of patients where HDV-RNA was not detected. Conclusion: The hepatitis flare related to chemotherapy occurred more frequently in B-Cell non-Hodgkin lymphoma patients coinfected with HBV and HDV without antiviral prophylaxis, especially when HDV-RNA was detected.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Results of the National Study of CLEIA Method for the Prevalence of HBV and HCV in the 40-64 Age Population of Mongolia
    (Mongolian National University of Medical Sciences, 2019-09-25) ; ; ; ;
    Objective: Using high-sensitivity test results of CLEIA we aimed to investigate the prevalence of hepatitis B and C virus, and compare levels of AST, ALT, M2BPGI in the Mongolian population in the age between 40-64. Methods: In order to reflect the administrative and geographical features of Mongolia, the sampling was done at three levels: urban, province center, and rural. Immunological test was measured by chemiluminescence enzyme immunoassay (CLEIA). The statistical package for the social sciences (SPSS) version 25 was used for the statistical analyses. Results: The survey covered 3196 people. 71.8 percent of the patients surveyed had a negative in hepatitis test. 10.1 percent had a positive HBsAg test. 17 percent had a positive anti-HCV test. 1.1 percent had both a positive both HBsAg and anti-HCV (<.0001). AST and ALT increased more frequently during co-infection. M2BPGI protein average level in the non-infected group was 1.00 C.O.I, in the HBsAg positive group 1.65 C.O.I, in the anti-HCV positive group 1.83 C.O.I, and in the co-infection group 1.87 C.O.I (<.0001). Conclusion:10.1 percent of 40-64year-olds in Mongolia were infected with hepatitis B virus, and 17 percent had Hepatitis C virus and 1.1 percent had hepatitis B and C virus co-infections. Serum M2BPGi is increasing in hepatitis C virus infection and in co-infection.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Anti-HCV, HBsAg Positive Incidences Among Patients Aged 40 Years and Over Diagnosed with B- Non-Hodgkin’s Lymphoma: A Comparison with General Population of Same Age
    (Mongolian National University of Medical Sciences, 2019-12-29) ;
    Delgerbat Boldbaatar
    ;
    Anir Enkhbat
    ;
    ;
    Khishigjargal Batsukh
    Objectives: There are several risk factors contribute to the development of the B-cell Non-Hodgkin’s lymphoma (B-NHL) among which hepatitis B, hepatitis C virus (HBV, HCV) infection, as well as old age, are known to have a signi cant effect. Previous studies examining the relationship between HBV, HCV infection and B-NHL show inconsistent results in different endemic areas. Methods: We compared the hepatitis B surface antigen (HBsAg) and antibody against the HCV (anti-HCV) positive incidences among aged 40 years or older patients who have been newly diagnosed with B-NHL, between 2015 and 2018, to prevalence of hepatitis B and C virus infection in the general population of Mongolia in the same age by data of the general population in hepatitis screening and the results of previous studies on the Mongolian population. Results: A total of 187 patients, newly diagnosed with B-NHL ≥40years of age took part in our study. In case of these two groups, the prevalence of HBsAg in the B-NHL population was close to the general population while anti-HCV positive was signi cantly higher in the B-NHL group (p<.00001). Conclusion: Further studies are needed to clarify the reasons and contributing factors which result situations where the HBV prevalence among B-NHL patients and the general population are not signi cantly different.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Comparison of Clinical Features of Hepatitis B and C Virus-Related Hepatocellular Carcinoma
    (Mongolian National University of Medical Sciences, 2022-09-30) ;
    Erdenebileg Taivanbaatar
    ;
    ; ;
    Objective: To compare the clinical characteristics of hepatitis B virus-related hepatocellular carcinoma (HBV group) and C virus-related hepatocellular carcinoma (HCV group). Methods: By a single century, we analyzed the clinical characteristics of 23 patients with hepatitis B virus-related hepatocellular carcinoma (HBV group) and 34 with hepatitis C virus-related hepatocellular carcinoma (HCV group). Results: The patients in the HBV group (mean age 61.1 year) were about 6 years younger than those in the HCV group (mean age 67.1 year). Liver function, as measured by indocyanine green retention at 15 min, was better in the HBV group (17.5 %) than in the HCV group (25.4 %). A higher proportion of the HBV group (55 %) than the HCV group (44 %) had clinical stage I. T-factor differed significantly between the groups: 53 % of the HBV group were T3 - 4 compared with 41 % of the HCV group. Furthermore, a higher proportion of the HBV group was graded 2 - 3 for tumor thrombus in the portal vein (20.3 %) and had poorly differentiated hepatocellular carcinoma (7 %) compared with the HCV group (7.1 % and 5 % respectively). Univariate analysis identified poor prognostic factors for hepatocellular carcinoma as HBV, age < or = 50 year, clinical stage II-III, a high AFP level, higher number of tumors, larger tumor size, tumor thrombus in the portal vein 2 - 3 and in the hepatic vein 2 - 3. On multivariate analysis, poor prognostic factors were a high AFP level, a higher number of tumors, and tumor thrombus in the portal vein 2 - 3 and in the hepatic vein 2 - 3, but not HBV, age, clinical stage, or tumor size. In the multiple logistic regression models on the hepatitis infection, the OR for ASAT was 2.01 (95 % CI 1.41 - 6.91), statistically significant (p < 0.05). Conclusion: These results suggest that HBV itself is not a stronger prognostic factor than HCV.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Establishment of Reference Interval for M2BPGI Glyco-Biomarker in the Serum of Mongolian People
    (Mongolian National University of Medical Sciences, 2020-12-29) ; ; ; ;
    Objectives: Establishment of reference interval for M2BPGI glyco-biomarker in the serum of relatively healthy Mongolian people. Methods: Serum analysis for M2BPGI glyco-biomarker, hepatitis virus markers, and AFP analysis were performed using a fully automated chemiluminescence immunoassay analyzer. Non-parametric methods were used for establishment of reference interval according to the guideline of the Clinical Laboratory Standards Institute. Statistical analysis was done by using SPSS ver. 20.0; SPSS Inc., Chicago, IL software. Results: Total of 3384 people were involved in this study. Of the total participants, 40% were overweight and 31.3% were obese. Also, of the population 10.1 percent were positive for HBsAg, 17 percent were positive for Anti-HCV, and 1.1 percent had co infection of both HBV and HCV. A total of the 316 individuals met the inclusion criteria for reference interval establishment and 77 (24.4%) of them were men and 239 (75.6%) were women. The reference interval of M2BPGI glyco-biomarker for men was 0.883 ± 0.311C.O.I and for women was 0.951 ± 0.411C.O.I. Conclusion: It is determined that the reference interval for M2BPGI glyco-biomarker in the serum of relatively healthy Mongolian people was 0.936 ± 0.391C.O.I.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Knowledge, Attitudes, and Practices (KAP) Regarding Hepatitis B Vaccination among Healthcare Workers in Mongolia
    (Scientific Research Publishing, 2023-01-01) ;
    Burmaajav Badrakh
    ;
    ;
    Byambaa Tumurbat
    ;
    Badamjav Amgalan
    Background: Mongolia is no exception and experiencing the burden of HBV among the population. In the last decade, the prevalence of HBV among the relatively healthy population of Mongolia has ranged between 11.8 percent and 10.6 percent, and acute cases are between 1.7 and 1.1 per 10,000 people. We aimed to determine healthcare workers (HCWs) knowledge, attitude, and practices regarding HBV prevention compared to vaccination coverage. Methods: This cross-sectional study was conducted among HCWs from the selected sites through multi-stage sampling. The study involved 1135 HCWs, including medical doctors, nurses, clinicians in both surgical and medical specialties, laboratory technicians, and other staff working in all departments from primary and referral levels in 36 healthcare facilities in two urban and four rural provinces of Mongolia. Participants who consented to the study completed a standardized self-administered questionnaire between July and Dec 2019. Results: Most participants (82.0%) were born before 1992 or before starting a birth vaccination against HBV in Mongolia. The mean age of the participants was 38 years and the participants’ median employment year in the health sector was seven years. Most participants were medical doctors (29.1%) and nurses (28.0%). Five questions explored HCWs’ knowledge about hepatitis B virus infection and prevention, and the correct response ranged between 15.6% and 95.4%. 2.8% of the respondents answered five questions correctly. Men, those with higher levels of education, those over the age of 30, soum family health center HCWs, and doctors and senior medical professionals answered many questions correctly, which is statistically significant. 98.9% of respondents believe that HCWs should vaccinate against HBV. The younger the age (%), management professionals, and service staff are confident in vaccines. A significant difference between age groups, perception of HBV infection, and formal attendance to the official training positively relate to vaccination coverage. Specially survey respondents who knew about the adverse effects of overdosing, learning about total doses of the vaccine, and the effectiveness of the hepatitis B vaccine were more tent to have full doses of the HBV vaccine. Knowledge and working conditions are increasing factors in receiving full doses of the HVB vaccine. Conclusion: The overall knowledge of HBV and its vaccination is fair among the HCWs; however, there is a need to intensify the training on some of the details and increase the training frequency at the workplace. Attitude and practice on infection protection and vaccination are still essential to be promoted among the HCWs. The low level of vaccination coverage is relevant to the level of KAP among the HCWs of the country.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories
    (Elsevier BV, 2023-11-27)
    Devin Razavi‐Shearer
    ;
    H. Child
    ;
    K. Razavi-Shearer
    ;
    Alexis S. Voeller
    ;
    Homie A. Razavi
    BACKGROUND & AIMS: Hepatitis delta virus (HDV) is a satellite RNA virus that requires the hepatitis B virus (HBV) for assembly and propagation. Individuals infected with HDV progress to advanced liver disease faster than HBV-monoinfected individuals. Recent studies have estimated the global prevalence of anti-HDV antibodies among the HBV-infected population to be 5-15%. This study aimed to better understand HDV prevalence at the population level in 25 countries/territories. METHODS: We conducted a literature review to determine the prevalence of anti-HDV and HDV RNA in hepatitis B surface antigen (HBsAg)-positive individuals in 25 countries/territories. Virtual meetings were held with experts from each setting to discuss the findings and collect unpublished data. Data were weighted for patient segments and regional heterogeneity to estimate the prevalence in the HBV-infected population. The findings were then combined with The Polaris Observatory HBV data to estimate the anti-HDV and HDV RNA prevalence in each country/territory at the population level. RESULTS: After adjusting for geographical distribution, disease stage and special populations, the anti-HDV prevalence among the HBsAg+ population changed from the literature estimate in 19 countries. The highest anti-HDV prevalence was 60.1% in Mongolia. Once adjusted for the size of the HBsAg+ population and HDV RNA positivity rate, China had the highest absolute number of HDV RNA+ cases. CONCLUSIONS: We found substantially lower HDV prevalence than previously reported, as prior meta-analyses primarily focused on studies conducted in groups/regions that have a higher probability of HBV infection: tertiary care centers, specific risk groups or geographical regions. There is large uncertainty in HDV prevalence estimates. The implementation of reflex testing would improve estimates, while also allowing earlier linkage to care for HDV RNA+ individuals. The logistical and economic burden of reflex testing on the health system would be limited, as only HBsAg+ cases would be screened. IMPACT AND IMPLICATIONS: There is a great deal of uncertainty surrounding the prevalence of hepatitis delta virus among people living with hepatitis B virus at the population level. In this study, we aimed to better understand the burden in 25 countries and territories, to refine techniques that can be used in future analyses. We found a lower prevalence in the majority of places studied than had been previously reported. These data can help inform policy makers on the need to screen people living with hepatitis B virus to find those coinfected with hepatitis delta virus and at high risk of progression, while also highlighting the pitfalls that other researchers have often fallen into.
    Scopus© Citations 121
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource-limited settings
    (2020-05)
    Gane, Edward John
    ;
    Charlton, Michael R
    ;
    Mohamed, Rosmawati
    ;
    Sollano, Jose Decena
    ;
    Tun, Kyaw Soe
    Asia has an intermediate-to-high prevalence of and high morbidity and mortality from hepatitis B virus (HBV) infection. Optimization of diagnosis and initiation of treatment is one of the crucial strategies for lowering disease burden in this region. Therefore, a panel of 24 experts from 10 Asian countries convened, and reviewed the literature, to develop consensus guidance on diagnosis and initiation of treatment of HBV infection in resource-limited Asian settings. The panel proposed 11 recommendations related to diagnosis, pre-treatment assessment, and indications of therapy of HBV infection, and management of HBV-infected patients with co-infections. In resource-limited Asian settings, testing for hepatitis B surface antigen may be considered as the primary test for diagnosis of HBV infection. Pre-treatment assessments should include tests for complete blood count, liver and renal function, hepatitis B e-antigen (HBeAg), anti-HBe, HBV DNA, co-infection markers and assessment of severity of liver disease. Noninvasive tests such as AST-to-platelet ratio index, fibrosis score 4 or transient elastography may be used as alternatives to liver biopsy for assessing disease severity. Considering the high burden of HBV infection in Asia, the panel adopted an aggressive approach, and recommended initiation of antiviral therapy in all HBV-infected, compensated or decompensated cirrhotic individuals with detectable HBV DNA levels, regardless of HBeAg status or alanine transaminase levels. The panel also developed a simple algorithm for guiding the initiation of treatment in noncirrhotic, HBV-infected individuals. The recommendations proposed herein, may help guide clinicians, to optimize the diagnosis and improvise the treatment rates for HBV infection in Asia.
    Scopus© Citations 16